Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus

Pediatric Diabetes

Volumn 18, Issue 8, 2017, Pages 903-910

  Fath, Maryam ^a   Danne, Thomas ^a   Biester, Torben ^a   Erichsen, Lars ^b   Kordonouri, Olga ^a   Haahr, Hanne ^b  

^a Diabetes Centre for Children and Adolescents   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

adolescents; children; pharmacodynamics; pharmacokinetics; type 1 diabetes mellitus

Indexed keywords

ARGININE; EXCIPIENT; GLUCOSE; INSULIN ASPART; NEUTRAL INSULIN; NICOTINAMIDE; SODIUM CHLORIDE; ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EXPOSURE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MAXIMUM CONCENTRATION; ONSET AGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; COMPARATIVE STUDY; DRUG EFFECT; YOUNG ADULT;

ADOLESCENT; AGE FACTORS; BLOOD GLUCOSE; CHILD; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN ASPART; MALE; YOUNG ADULT;

EID: 85012906465     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12506     Document Type: Article

References (27)

1. Wood JR, Miller KM, Maahs DM, et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care. 2013;36:2035–2037.
2. Chiang JL, Kirkman MS, Laffel LM, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014;37:2034–2054.
3. Rewers MJ, Pillay K, de Beaufort C, et al. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(suppl20):102–114.
4. Petit-Bibal C, Rothenbuhler A, Lucchini P, et al. Decrease in clinical hypoglycemia in young children with type 1 diabetes treated with free-mixed aspart and detemir insulin: an open labelled randomized trial. Pediatr Diabetes. 2015;16:345–353.
5. Danne T, Bangstad HJ, Deeb L, et al. ISPAD Clinical Practice Consensus Guidelines 2014. Insulin treatment in children and adolescents with diabetes. Pediatr Diabetes. 2014;15(suppl 20):115–134.
6. Danne T. Flexibility of rapid-acting insulin analogues in children and adolescents with diabetes mellitus. Clin Ther. 2007;29(suppl D):S145–S152.
7. Mortensen HB, Lindholm A, Olsen BS, Hylleberg B. Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes. Eur J Pediatr. 2000;159:483–488.
8. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care. 2005;28:2100–2105.
9. Boland E, Monsod T, Delucia M, Brandt CA, Fernando S, Tamborlane WV. Limitations of conventional methods of self-monitoring of blood glucose: lessons learned from 3 days of continuous glucose sensing in pediatric patients with type 1 diabetes. Diabetes Care. 2001;24:1858–1862.
10. Cengiz E. Undeniable need for ultrafast-acting insulin: the pediatric perspective. J Diabetes Sci Technol. 2012;6:797–801.
11. Food and Drug Administration. Inactive ingredient search for approved drug products. http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm. Accessed January 23, 2017.
12. Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–688.
13. ICH Harmonised Tripartite Guideline E11. Clinical investigation of medicinal products in the pediatric population. 20 July 2000. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E11/Step4/E11_Guideline.pdf. Accessed January 23, 2017.
14. European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on the Role of Pharmacokinetics in the Development of Medicinal Products in the Paediatric Population. 28 June 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003066.pdf. Accessed January 23, 2017.
15. U.S. Food and Drug Administration. Guidance for Industry. General Considerations for Pediatric Pharmacokinetic Studies for Drugs and Biological Products November 1998. http://www.fda.gov/ohrms/dockets/ac/03/briefing/3927B1_04_GFI-Pharmacokinetic%20Guidance.pdf. Accessed January 23, 2017.
16. Biester T, Danne T, Bläsig S, et al. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes. Pediatr Diabetes. 2016;17:642–649.
17. American Diabetes Association. Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on hypoglycaemia. Diabetes Care. 2005;28:1245–1249.
18. Fieller EC. Some problems in interval estimation. J R Stat Soc Series B Stat Methodol. 1954;16:175–185.
19. Russell-Jones D, Bode B, de Block C, et al. Double-blind mealtime faster-acting insulin aspart vs insulin aspart in basal–bolus improves glycemic control in T1D: the onset® 1 trial. Diabetes. 2016;65(suppl1):A77.
20. Cobry E, McFann K, Messer L, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12:173–177.
21. Danne T, Aman J, Schober E, et al. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care. 2003;26:2359–2364.
22. Heise T, Zijlstra E, Nosek L, Rikte T, Haahr H. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial. Diabetes Obes Metab. 2016. doi: 10.1111/dom.12803 [Epub ahead of print]
23. Pozzilli P, Battelino T, Danne T, Hovorka R, Jarosz-Chobot P, Renard E. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. Diabetes Metab Res Rev. 2016;32:21–39.
24. Phillip M, Battelino T, Rodriguez H, Danne T, Kaufman F. Use of insulin pump therapy in the pediatric age-group. Diabetes Care. 2007;30:1653–1662.
25. Sherr JL, Hermann JM, Campbell F, et al. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59:87–91.
26. Danne T, Tamborlane WV. Insulin pumps in pediatrics: we have the technology. We have the evidence. Why are still so few kids using it? Pediatr Diabetes. 2006;7(suppl 4):2–3.
27. Kovatchev B, Tamborlane WV, Cefalu WT, Cobelli C. The artificial pancreas in 2016: a digital treatment ecosystem for diabetes. Diabetes Care. 2016;39:1123–1126.